Dose of reality: The fragile backbone of cancer compounding services

Brendan Cummins, Vice President and General Manager ANZ at Baxter Healthcare, dives into the evolving ecosystem of TGA licensed compounding services – a critical pillar in cancer care across Australia, including remote and rural communities. At the heart of the conversation is a pressing question: how sustainable is the current compounding model?

As cancer treatments become increasingly complex and personalised, compounding services have had to keep pace. Cummins shares how the landscape has shifted over the past decade to meet these growing demands, highlighting why a new report was commissioned to examine the sustainability of the sector.

The discussion also takes a broader look at the policy environment, particularly the 2023 review of the Efficient Funding of Chemotherapy (EFC) arrangements – a report that remains without a formal government response.

With the Department of Health juggling numerous projects under a lean budget and resources cuts, Cummins weighs in on where compounding services reform will realistically fit on the Health Minister Mark Butler’s agenda.

He also points to the broader implications if the current supply chain – in which 66% of compounded medicines are provided by TGA-licensed providers like Baxter – were to become unsustainable.

This is not just a conversation about supply logistics; it’s a lens into how a critical healthcare service is navigating increased regulatory standards, economic pressure, and the expectations of a rapidly changing patient population.

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.

The Health Industry Hub^TM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.